Skip to main content

Table 2 Score to evaluate the benefits of the treatment with chemo-immunotherapy in dogs with DLBCL and MZL

From: Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers

Serum LDH levels Normal (0) Increased (+ 1)
Stage III/IV (0) V (+ 1)
Substage b (0) a (+ 1)
Steroids before referral Yes (0) No (+ 1)
Dogs with diffuse large B-cell lymphoma
Score Median LSS 1-year SR 2-year SR 3-year SR
CH CH-IM P CH CH-IM CH CH-IM CH CH-IM
4 (n = 27) 85 480 < 0.001* 0% 57% 0% 15% 0% 0%
2–3 (n = 99) 190 435 0.030* 23% 50% 12% 18% 8% 11%
0–1 (n = 22) 286 374 0.573 40% 45% 40% 27% 25% 11%
All cases (n = 148) 165 413 0.001* 20% 51% 13% 19% 8% 10%
Dogs with marginal zone lymphoma
Score Median LSS 1-year SR 2-year SR 3-year SR
CH CH-IM P CH CH-IM CH CH-IM CH CH-IM
3–4 (n = 29) 160 680 < 0.001* 9% 77% 0% 36% 0% 12%
0–2 (n = 20) 560 172 0.165 56% 14% 38% 14% 25% 0%
All cases (n = 49) 254 399 0.245 30% 55% 16% 28% 10% 10%
  1. Abbreviations: LDH, lactate dehydrogenase; LSS, lymphoma specific survival; SR, survival rate; CH, chemotherapy; CH-IM, chemo-immunotherapy
  2. * Significant